Excitedly, in a recent study, the inhibition of IGF-1R using linsitinib reversed oncogenic function caused by the loss and/or downregulation of methylthioadenosine phosphorylase in RCC [56]. This evidence concerns the gene IGF1R and renal cell carcinoma.